Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : NOVARTIS
Femme et Homme Max 99 ans
NOVARTIS
MAJ Il y a 4 ans
Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma
This study will investigate the safety and tolerability of indacaterol maleate/mometasone furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate asthma...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b in treating the cognitive symptoms associated to relapsing-remitting multiple sclerosis and to assess possible relationship of these effects to regional brain atrophy
The primary objective of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduct...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS
MAJ Il y a 4 ans
An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever
This study will investigate whether a single dose QAX576 (an interleukin-13 monoclonal antibody) gives protection against a model of hayfever
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
An extension to a phase II study to determine the efficacy and the safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha estensione dello uno studio di fase II per determinare l`efficacia e la sicurezza di STI 571 in pazienti con LMC refrattari o intolleranti alla terapia con interferone-alfa
To decrease the frequency of bone marrow evaluations to once a year from once every 6 months for all patients who have achieved a complete cytogenetic response. This study objective has been met as ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multicenter study to evaluate the safety, tolerability, and disease modifying efficacy of daily oral AAE581 (10, 25 and 50 mg tablets) in patients with painful knee osteoarthritis, Kellgren-Lawrence grade 3 by X-ray
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A study to investigate whether LJM716 in combination with cetuximab is safe and has beneficial effects in patients with advanced head and neck cancer who progressed on prior therapy
Phase Ib: To determine RP2D and estimate MTD of LJM716 in combination with cetuximab in patients with RM HNSCC Phase II: To access the anti-tumor activity of LJM716-cetuximab combination in cetuxima...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy
The primary objective of the study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care, using the global...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in addition to Certican 61668; and Steroids in de novo Heart Transplant Recipients
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
To evaluate the impact of early vs delayed introduction of everolimus on wound healing in patients newly transplanted kidney Valutazione dell'impatto dell'introduzione precoce di everolimus rispetto a quella ritardata sulla guarigione della ferita in pazienti appena trapiantati di rene
The primary objective of the study is to compare the proportion of patients without wound complications related to initial transplant surgery (i.e. lymphorrea, fluid collections, wound dehiscence, wou...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 when administered in combination with oral lenalidomide & dexamethasone in adult patients with multiple myeloma Studio multicentrico, di fase Ib in aperto, di incremento della dose di LBH589 somministrato per via orale in associazione a lenalidomide e desametasone per via orale in pazienti adulti con mieloma multiplo
To determine the MTD of LBH589 when used in combination with a fixed dose of lenalidomide & dexamethasone. Determinare la MTD di LBH589 somministrato per via orale in associazione a una dose fi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
3
4
5
6
7
8
9
10
Suivant